Details

Autor(en) / Beteiligte

• Frobert, Emilie
• Burrel, Sonia
• Ducastelle-Lepretre, Sophie
• Billaud, Geneviève
• Ader, Florence
• Casalegno, Jean-Sébastien
• Nave, Viviane
• Boutolleau, David
• Michallet, Mauricette
• Lina, Bruno
• Morfin, Florence

Titel

Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France

Ist Teil von

• Antiviral research, 2014-11, Vol.111, p.36-41

Ort / Verlag

Kidlington: Elsevier B.V

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •In immunocompetent patients, HSV resistance to ACV has not increased.•In immunocompromised patients, HSV resistance to ACV increased significantly from 3.8% in 2002–2006 to 15.7% in 2007–2011.•The increase was represented by HSCT patients, wherein the prevalence rose from 14.3% in 2002–2006 to 46.5% in 2007–2011.•Resistance in other types of immune deficiencies did not increase.•11 and 7 previously unreported substitutions were characterized in the UL23 and UL30 genes, respectively. The widespread use of acyclovir (ACV) and the increasing number of immunocompromised patients have raised concern about an increase in ACV-resistant herpes simplex virus (HSV). ACV resistance has traditionally been a major concern for immunocompromised patients with a frequency reported between 2.5% and 10%. The aim of this study was to reassess the status of HSV resistance to ACV in immunocompetent and immunocompromised patients over a ten year period, between 2002 and 2011. This was done by retrospectively following 1425 patients. In immunocompetent patients, prevalence of resistance did not exceed 0.5% during the study period; whereas in immunocompromised patients, a significant increase was observed, rising from 3.8% between 2002 and 2006 (7/182 patients) to 15.7% between 2007 and 2011 (28/178) (p=0.0001). This sharp rise in resistance may largely be represented by allogeneic hematopoietic stem cell transplant patients, in which the prevalence of ACV resistance rose similarly from 14.3% (4/28) between 2002 and 2006 to 46.5% (26/56) between 2007 and 2011 (p=0.005). No increase in ACV resistance was detected in association with other types of immune deficiencies. Genotypic characterization of HSV UL23 thymidine kinase and UL30 DNA polymerase genes revealed 11 and 7 previously unreported substitutions, respectively. These substitutions may be related to potential polymorphisms, drug resistance, or other mutations of unclear significance.